Sobi agreed to acquire Arthrosi Therapeutics for $950 million in cash with up to $550 million in milestones, securing pozdeutinurad (AR882), a Phase‑3 URAT1 inhibitor for progressive gout. The deal was announced by Sobi and Arthrosi executives and will be financed largely with debt facilities arranged with Handelsbanken and Danske Bank. Pozdeutinurad is being evaluated in two global Phase‑3 trials that are fully enrolled, with pivotal readouts expected in 2026. Arthrosi’s management and investors opted for an acquisition rather than an IPO after a $153 million Series E. Sobi’s CEO Guido Oelkers framed the asset as a potential near‑term commercial driver for the company. The transaction consolidates competing URAT1 programs and underscores buyer appetite for late‑stage, specialty rheumatology assets that can address unmet needs beyond allopurinol. Safety questions around earlier URAT1 drugs (e.g., renal signals that sank prior programs) will be central to regulatory review and commercial positioning as readouts approach.